DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28687340Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28687340
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709
Angiotensin III (Ang III) is a bioactive heptapeptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A. In peripheral Angiotensin systems, Angiotensin II is the main effector peptide in the systemic circulation, although exogenous Angiotensin III can be as potent as Angiotensin II in, for example, stimulating aldosterone secretion or inhibiting renin release. In the rat brain, Angiotensin III was found to be equipotent with Angiotensin II as a pressor agent or dipsogen and was bound as avidly to the nervous system as Angiotensin II. Angiotensin receptor subtype AT1 has the greater affinity towards Angiotensin II and is also responsive to Angiotensin III, while the AT2 receptor subtype appears to be more sensitive to Angiotensin III but less responsive to Angiotensin II. Angiotensin III enhances blood pressure, vasopressin release and thirst when it is centrally administrated. Angiotensin III infusion increases blood pressure in healthy volunteers and hypertensive patients as well as augments aldosterone release. Although Angiotensin III does not change renal function in humans, it induces natriuresis in AT, receptor-blocked rats likely by binding to AT2 receptors. In addition, in cultured renal cells, this peptide stimulates the expression of many growth factors, proinflammatory mediators, and extracellular matrix proteins.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
5.57 nM [IC50] | ||
Target ID: CHEMBL4607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8515427 |
1.74 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The biochemistry of the renin-angiotensin system and its role in hypertension. | 1976 May 31 |
|
The brain renin-angiotensin system. | 1984 |
|
Control of intestinal absorption by the renin-angiotensin system. | 1985 Jul |
|
The mas oncogene as a neural peptide receptor: expression, regulation and mechanism of action. | 1990 |
|
[Active metabolites derived from angiotensin II]. | 1998 |
|
Bioactive angiotensin peptides. | 1998 May |
|
Brain aminopeptidases and hypertension. | 2006 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16380540
Ang III (3.5, 7, and 14 nmol/kg per minute) was infused cumulatively into the renal interstitialspace of the left (experimental) kidney each rat after a 1-hour control infusion
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18677709
Human prostate cancer cell (DU145 and LNCaP) were used for activity evaluation. LNCaP and DU145 cells were seeded onto 24-well plates at a density of 2–5x10^4 cells/well. Cells were treated with Ang-III at various concentrations as indicated in the figures for 5 days. Simultaneously, the cells were pretreated with olmesartan for 30 min, and cultured in phenol red-freeRPMI plus 0.1% BSA in the presence of Ang-III for 5 days. After incubation in 5% CO2 at 37C, cells were harvested with trypsin and cell numbers were determined with a cell counter on day 5.
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 09:22:13 GMT 2023
by
admin
on
Sat Dec 16 09:22:13 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
XH7F04LXTF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3082042
Created by
admin on Sat Dec 16 09:22:13 GMT 2023 , Edited by admin on Sat Dec 16 09:22:13 GMT 2023
|
PRIMARY | |||
|
13602-53-4
Created by
admin on Sat Dec 16 09:22:13 GMT 2023 , Edited by admin on Sat Dec 16 09:22:13 GMT 2023
|
PRIMARY | |||
|
12687-51-3
Created by
admin on Sat Dec 16 09:22:13 GMT 2023 , Edited by admin on Sat Dec 16 09:22:13 GMT 2023
|
ALTERNATIVE | |||
|
XH7F04LXTF
Created by
admin on Sat Dec 16 09:22:13 GMT 2023 , Edited by admin on Sat Dec 16 09:22:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INGREDIENT -> STARTING MATERIAL |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|